Notice regarding progress in core business, impairment loss and revision of financial forecasts for FY2024

Jan 24, 2025

U.S. FDA confirms class 1 resubmission of the Supplemental new drug application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Jan 09, 2025

China’s National Medical Products Administration (NMPA) approves PADCEVTM in combination with KEYTRUDA® (pembrolizumab) for the treatment of advanced bladder cancer

Jan 08, 2025